Intervention Profiles

Spermidine and autophagy: what the human evidence actually shows

A naturally occurring polyamine, studied for the same autophagy pathway that gives rapamycin its mechanistic case — with a much earlier-stage human evidence base.

June 24, 2026  ·  8 min read

Acarbose for longevity: the ITP mouse data and human diabetes evidence

A decades-old diabetes drug extends lifespan in a rigorous mouse program — but its human longevity evidence tells a different, more limited story.

June 24, 2026  ·  9 min read

17α-Estradiol: a lifespan effect with a sex-specific puzzle

A non-feminizing estrogen extends lifespan in male mice in NIA-backed data — and shows no comparable effect in females. What the evidence shows, and what remains unexplained.

June 23, 2026  ·  10 min read

Taurine and longevity: what the evidence actually shows

A 2023 mouse study reignited interest in an amino acid most people associate with energy drinks. Here is what the data shows, what it doesn't, and why Geroevidence hasn't assigned it an evidence tier yet.

June 23, 2026  ·  9 min read

Rapamycin for longevity: what the clinical evidence actually shows in 2026

A structured synthesis of every published human trial and major animal study — evidence strength rated honestly, with what is known, what is unknown, and what trials are ongoing.

May 13, 2026  ·  14 min read

GLP-1 agonists beyond weight loss: the cardiovascular and longevity evidence

Semaglutide and tirzepatide are the most prescribed drugs in medicine. The weight loss story is well known. The cardiovascular and longevity evidence is more important and less understood.

May 13, 2026  ·  12 min read

SGLT2 inhibitors and aging: what the evidence actually shows

Empagliflozin and dapagliflozin have some of the strongest cardiovascular and renal outcomes data in medicine. Their longevity relevance is underappreciated. Here is the evidence.

May 13, 2026  ·  10 min read